Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000778 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
A Phase 1 study of HIV Infections and Tuberculosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 10
- Study locations
NCT00000778: Completed Phase 1 study of HIV Infections and Tuberculosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000778 is a Phase 1 study of HIV Infections and Tuberculosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 44 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000778, a Phase 1 study of HIV Infections and Tuberculosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 10
- Study locations
Study Summary
To evaluate the methodology for rapidly determining the early bactericidal activity (EBA), tolerance, and pharmacokinetics of isoniazid and levofloxacin in the treatment of pulmonary tuberculosis (TB). Traditionally, in trials for treatment of TB, a new drug is administered in combination with two or more other antituberculous agents of known effectiveness over a long period of time. In this setting, it is difficult to determine the effect of any single drug or dose level. Development of new agents for the treatment of TB may be accelerated by a methodology in which a new agent could be evaluated for activity by administering it as a single agent over a short time period. This study utilizes a method to measure the amount of bacteria present each day in the lungs.
Conditions Studied
Interventions
- DRUG Isoniazid
- DRUG Pyridoxine hydrochloride
- DRUG Levofloxacin
Study Locations (10)
Texas
- Univ of Texas Southwestern Med Ctr of Dallas - Dallas
- Univ TX Galveston - Galveston
- Baylor College of Medicine / Houston Veterans Adm Med Ctr - Houston
California
- UCLA Med Ctr - Los Angeles
- Harbor - UCLA Med Ctr - Torrance
Florida
- Broward Gen Med Ctr - Fort Lauderdale
- Univ of Miami / Jackson Memorial Hosp - Miami
Alabama
- Univ of Alabama at Birmingham - Birmingham
Illinois
- Univ of Illinois - Chicago
Louisiana
- Tulane Univ Med School - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Phase | Phase 1 |
What the finished NCT00000778 record still lists
NCT00000778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Isoniazid is the first listed.
NCT00000778 lists 10 locations in 6 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT00000778 about?
NCT00000778 is a clinical study titled "A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin". To evaluate the methodology for rapidly determining the early bactericidal activity (EBA), tolerance, and pharmacokinetics of isoniazid and levofloxacin in the treatment of pulmonary tuberculosis (TB). Traditionally, in trials for treatment of TB, a new drug is administered in combination with two ...
What is the current status of trial NCT00000778?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants.
What conditions does trial NCT00000778 study?
This clinical trial studies the following conditions: HIV Infections, Tuberculosis.
What interventions are being tested in trial NCT00000778?
The interventions under investigation include: Isoniazid (DRUG), Pyridoxine hydrochloride (DRUG), Levofloxacin (DRUG).
Who is sponsoring clinical trial NCT00000778?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000778 being conducted?
This trial has 10 study locations across Alabama, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000778's enrollment target sits among peer trials
44 380th of 542 higher than 159 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk